

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



天津泰達生物醫學工程股份有限公司  
**Tianjin TEDA Biomedical Engineering Company Limited**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 8189)**

**RE-DESIGNATION OF DIRECTOR AND  
CHANGE OF CHIEF EXECUTIVE OFFICER**

The Board announced that Mr. Hao Zhihui (郝志輝), an executive Director of the Company, has been appointed as the vice-chairman of the Board on 20 April 2011 and resigned as the chief executive officer of the Company on the same date.

In addition, the Board also announced that Mr. Zhang Chunsheng (張春生) has been appointed as the chief executive officer of the Company with effect from 20 April 2011.

**RE-DESIGNATION OF DIRECTOR AND RESIGNATION OF CHIEF EXECUTIVE OFFICER**

The Board of Directors (the “Board”) of Tianjin TEDA Biomedical Engineering Company Limited (the “Company”) announced that Mr. Hao Zhihui (郝志輝), an executive Director of the Company, has been appointed as the vice-chairman of the Board on 20 April 2011 and resigned as the chief executive officer of the Company on the same date.

Mr. Hao Zhihui (“Mr. Hao”), aged 50, has been appointed as an executive director of the Company since May 2009. He graduated from Tianjin Medical University in August 1984 with a bachelor’s degree in medicine and thereafter taught in the University till 1995. He also completed his master’s degree in Medicine offered by the same university in August 1992. From May 1995 to August 1997, he was in charge of production and technology in DPC (Tianjin) Co., Ltd (天津德普生物技術和醫學產品有限公司). From September 1997 to September 2000, he worked in Tianjin TEDA International Incubator as the head of the Medicine Industry Department (醫藥產業部部長). From September 2002 to March 2004, he studied Business Administration Major in the School of Continuing Education of Tsinghua University. From September 2000 to August 2006, he assumed the posts of chief investment

officer, chairman of the Supervisory Committee and executive vice president (常務副總裁) in the Company. He has been the President of the Company since August 2006. He also has been appointed as the director of Guangdong Fulilong Compound Fertilizers Co., Ltd. and Tianjin Alpha HealthCare Products Co., Ltd.

Mr. Hao has entered into a service contract with the Company with a term of three years commencing from 1 January 2011 and expiring on 31 December 2013. The existing annual emoluments of Mr. Hao is RMB250,000 which is determined on the basis of prevailing market rate, scope of work, level of involvement, experience, seniority and the recommendation of the remuneration committee of the Company.

## **APPOINTMENT OF CHIEF EXECUTIVE OFFICER**

In addition, the Board announced that Mr. Zhang Chunsheng (張春生) has been appointed as the chief executive officer of the Company with effect from 20 April 2011.

Mr. Zhang Chunsheng (“Mr. Zhang”), aged 44, graduated in 1989 with a bachelor degree. After graduation from university, Mr. Zhang had worked in various bureaus of People’s Government of Guangdong Province as officer, senior officer, principal officer, deputy division director, division director and deputy director-general. During 2005 to 2009, Mr. Zhang worked in the Hong Kong Representative Office of the Central Government, and in 2010, he was appointed as the chairman of a Hong Kong company, Pleasant Culture Media Co., Limited (大自在文化傳播公司) and has been appointed as the chairman of Shenzhen Xiangyong Investment Company Limited (“Xiangyong Investment”) since 2010 and holds all of its shares. Xiangyong Investment is a substantial shareholder of the Company, holding 180,000,000 domestic shares of the Company, representing approximately 12.68% of the issued share capital of the Company.

Save as disclosed above, each of Mr. Hao and Mr. Zhang currently does not hold any other position with the Company or other members of the Company’s group, and has not held any position in other companies listed in Hong Kong or any overseas securities market for the last three years.

Mr. Hao does not hold any interest or short position in any share, underling share or debenture of the Company which are required to be disclosed under Part XV of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

In addition, Mr. Hao is independent of and not connected with any promoter, Director, supervisor, senior management, management shareholders, other substantial shareholders, or controlling shareholders of the Company or any of its subsidiaries or their respective associates.

In addition, the Board is not aware of any other matters which has to be brought to the attention of holders of securities of the Company in respect of the redesignation of Director nor there is any other information required to be disclosed pursuant to any requirements set out in Rule 17.50(2) of the GEM Listing Rules.

By order of the Board  
**Tianjin TEDA Biomedical Engineering Company Limited**  
**Wang Shuxin**  
*Chairman*

Tianjin, China  
20 April 2011

*As at the date of this announcement, the Board comprises three executive Directors, being Mr. Wang Shuxin, Mr. Hao Zhihui and Mr. Xie Kehua; three non-executive Directors, being Mr. Feng Enqing, Mr. Xie Guangbei and Mr. Wei Jingquan and three independent non-executive Directors, being Mr. Cao Kai, Mr. Wu Chen and Mr. Guan Tong.*

*This announcement, for which the directors of the Company (the “Directors”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (“GEM”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this notice is accurate and complete in all material respects and not misleading or deceptive; (2) there are no other matters the omission of which would make any statement in this notice misleading; and (3) all opinions expressed in this notice have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*The announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for at least 7 days from the date of its posting.*